Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays.

Wilham JM, Orrú CD, Bessen RA, Atarashi R, Sano K, Race B, Meade-White KD, Taubner LM, Timmes A, Caughey B. · 2010

Read Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. by Wilham JM, Orrú CD, Bessen RA, Atarashi R, Sano K, Race B, Meade-White KD, Taubner LM, Timmes A, Caughey B. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2996325.txt.

Introduction

Wilham and co-authors described a lab test that counts prion seeding activity in about two days, in a 2010 article. Prion diseases resisted fast measurement, forcing slow animal tests to gauge tiny amounts of the infectious protein.

Their method seeds a shaking reaction that converts normal prion protein into fibrous clumps, watched in real time. Testing serial dilutions yields a dose estimate like classic animal end-point assays. Hamster brain samples gave values matching animal test sensitivity. Comparable speed and sensitivity could transform diagnosis and safety screening for blood and tissue products.

Catalog record

CREATORWilham JM, Orrú CD, Bessen RA, Atarashi R, Sano K, Race B, Meade-White KD, Taubner LM, Timmes A, Caughey B.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE58 KB
LICENSECC0 1.0 Universal
RIGHTSCC0
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2996325

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Rapid End-Point Quantitation of Prion Seeding Activity with Sensitivity Comparable to Bioassays By Jason M Wilham, Christina D Orrú, Richard A Bessen, Ryuichiro Atarashi, Kazunori Sano, Brent Race, Kimberly D Meade-White, Lara M Taubner, Andrew Timmes, Byron Caughey, David Westaway Published in: PLoS Pathogens DOI: 10.1371/journal.ppat.1001217 ABSTRACT Abstract A major problem for the effective diagnosis and management of prion diseases is the lack of rapid high-throughput assays to measure low levels of prions. Such measurements have typically required prolonged bioassays in animals. Highly sensitive, but generally non-quantitative, prion detection methods have been developed based on prions' ability to seed the conversion of normally soluble protease-sensitive forms of prion protein to protease-resistant and/or amyloid fibrillar forms. Here we describe an approach for estimating the relative amount of prions using a new prion seeding assay called real-time quaking induced conversion assay (RT-QuIC). The underlying reaction blends aspects of the previously described quaking-induced conversion (QuIC) and amyloid seeding assay (ASA) methods and involves prion-seeded conversion of the alpha helix-rich form of bacterially expressed recombinant PrPC to a beta sheet-rich amyloid fibrillar form. The RT-QuIC is as sensitive as the animal bioassay, but can be accomplished in 2 days or less. Analogous to end-point dilution animal bioassays, this approach involves testing of serial dilutions of samples and statistically estimating the seeding dose (SD) giving positive responses in 50% of replicate reactions (SD50). Brain tissue from 263K scrapie-affected hamsters gave SD50 values of 1011-1012/g, making the RT-QuIC similar in sensitivity to end-point dilution bioassays. Analysis of bioassay-positive nasal lavages from hamsters affected with transmissible mink encephalopathy gave SD50 values of 103.5–105.7/ml, showing that nasal cavities release substantial prion infectivity that can be rapidly detected. Cerebral spinal fluid from 263K scrapie-affected hamsters contained prion SD50 values of 102.0–102.9/ml. RT-QuIC assay also discriminated deer chronic wasting disease and sheep scrapie brain samples from normal control samples. In principle, end-point dilution quantitation can be applied to many types of prion and amyloid seeding assays. End point dilution RT-QuIC provides a sensitive, rapid, quantitative, and high throughput assay of prion seeding activity. INTRODUCTION The transmissible spongiform encephalopathies (TSEs) or prion diseases are fatal neurodegenerative disorders that include human Creutzfeldt-Jakob disease (CJD), bovine spongiform encephalopathy (BSE), sheep scrapie, cervid chronic wasting disease (CWD), and transmissible mink encephalopathy (TME). The infectious agent, or prion, of the TSEs appears to be composed primarily of an abnormal, misfolded, oligomeric form of prion protein (PrPSc). PrPSc is formed post-translationally from the normal cellular prion protein (PrPC) [1], [2]. PrPSc, which in purified form can resemble amyloid fibrils, induces the polymerization and conformational conversion of PrPC to infectious PrPSc [3]–[5] or to PrPSc-like partially protease-resistant forms (PrPres) in a variety of in vitro reactions [4], [6]–[8]. These studies demonstrate that PrPSc can self-propagate, and although the mechanism is not fully understood, it appears to be a seeded or templated polymerization [9]–[11]. The ability to detect prions rapidly and sensitively would be an important asset in managing TSEs. Early prion detection in individuals is critical to the prevention of spread and the initiation of potential treatments. Prions can be found in a wide variety of tissues and accessible bodily fluids from infected mammalian hosts, including blood [12]–[17], breast milk [18], [19], saliva [15], [20], urine [21], [22], feces [23], and nasal fluids [24]. In most cases, our ability to rapidly measure prion infectivity in these fluids is limited by the low amount of infectious agent. Knowledge of the prion titers in these fluids or tissues and their products is key for prion diagnosis and in assessing the public health exposure risks to those materials. The most direct and reliable assay for the detection of TSE infectivity is animal bioassay. Quantitation of infectivity can be achieved by end-point [25] or limiting dilution bioassays [26]. For some combinations of prion agent and host species, strong correlations between infectivity titer and disease incubation period have been established in laboratory rodents, allowing the use of incubation period to measure infectivity levels [27], [28]. The disadvantage of these bioassays is that they are animal-intensive, time-consuming and expensive. For certain murine-adapted scrapie strains, the cell culture based standard scrapie cell assay (SSCA) can also be used to measure infectivity levels by end-point and limiting dilution methods [29]. The SSCA offers several advantages over animal bioassays but it still requires weeks to perform and has been limited to a few mouse-adapted scrapie strains. The limitations of the animal bioassay and SSCA have provided strong motivation to develop more practical assays for prion quantitation. Several extremely sensitive in vitro methods for prion detection have been reported. Using the protein misfolding cyclic amplification (PMCA) reaction in multi-round sonicated reactions with brain-derived PrPC as a substrate, as little as 1 ag of PrPsc can be detected [30]. The speed and practicality of PMCA assays have been improved by the use of bacterially-expressed recombinant PrPC (rPrPc) [31] and by substituting shaking for the sonication step as described for quaking-induced conversion (QuIC) reactions [32], [33]. The QuIC assay can detect sub-femtogram amounts of PrPSc (less than one lethal intracerebral dose) in hamster brain homogenates (BH) within a single day. The effectiveness of the QuIC assay for prion detection was demonstrated by its ability to discriminate normal from prion-infected hamsters using 2 µl samples of cerebral spinal fluid (CSF) [32], [33] or nasal lavage [24]. The latest adaptations of QuIC reactions have led to the sensitive detection of variant CJD (vCJD) in human tissue and scrapie in sheep tissue [33]. The readout for QuIC and PMCA assays is the detection of specific protease-resistant prion-seeded products by immunoblotting, which is difficult to adapt to automated high-throughput formats. An alternative, and potentially higher-throughput approach was used for the amyloid seeding assay (ASA) in which the fluorescent dye thioflavin T (ThT) was used to detect prion seeding of rPrPC polymerization [34]. The ASA can also detect protease sensitive disease-causing prions and has a 98% correlation with neuropathological signs of prion disease [35]. However, a potentially confounding aspect of ASA is the frequent spontaneous formation of rPrP fibrils (without seeding by prions) soon after prion-seeded reactions [34]. Until very recently, a major limitation of the PMCA, QuIC and ASA methods was the lack of prion quantitation. While the present paper was under review, Chen and colleagues reported a method called quantitative PMCA (qPMCA) in which PrPSc content is estimated by the number of PMCA rounds necessary for a positive response [36]. Here we describe a distinct end-point dilution approach to relative prion quantitation with in vitro prion seeding assays which is analogous to the end-point dilution titrations classically used in animal bioassays. At the same time, we describe a new prion-seeded rPrPc polymerization assay, real-time (RT)-QuIC, which combines several aspects of the QuIC assay (intermittent shaking, rPrPC preparation, sample preparation, and a lack of chaotropic salts) with a fluorescent ThT readout, but with greatly reduced spontaneous rPrP fibril formation. Some elements of this new assay were first developed using human rPrPc and designated “real-time QUIC” by analogy with real-time PCR (R. Atarashi, K. Satoh, K. Sano, T. Fuse, N. Yamaguchi, D. Ishibashi, T. Matsubara, T. Nakagaki, H. Yamanaka, S. Shirabe, M. Yamada, H. Mizusawa, T. Kitamoto, G. Klug, A. McGlade, S. J. Collins,

Read the complete text